Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (167K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (42)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Giles, R. V.
Right arrow Articles by Tidd, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giles, R. V.
Right arrow Articles by Tidd, D. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, Vol 26, Issue 7 1567-1575, Copyright © 1998 by Oxford University Press


ARTICLES

Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells

RV Giles, DG Spiller, J Grzybowski, RE Clark, P Nicklin and DM Tidd
School of Biological Sciences, University of Liverpool, Life Science Building, Crown Street, Liverpool L69 7ZB, UK. giles@liv.ac.uk

It is widely accepted that most cell types efficiently exclude oligonucleotides in vitro and require specific delivery systems, such as cationic lipids, to enhance uptake and subsequent antisense effects. Oligonucleotides are not readily transfected into leukaemia cell lines using cationic lipid systems and streptolysin O (SLO) is used to effect their delivery. We wished to investigate the optimal oligonucleotide composition for antisense efficacy and specificity following delivery into leukaemia cells using SLO. For this study the well characterised chronic myeloid leukaemia cell line KYO-1 was selected and oligonucleotides (20mers) were targeted to an empirically identified accessible site of c- myc mRNA. The efficiency and specificity of antisense effect was measured 4 and 24 h after SLO-mediated delivery of the oligonucleotides. C5-propyne phosphodiester and phosphorothioate compounds were found to present substantial non-specific effects at 20 microM but were inactive at 0.2 microM. Indeed, no antisense-specific effect was noted at any concentration at either time. All of the other oligonucleotides tested induced some measurable antisense effect, except 7 (chimeric, all-phosphorothioate, 2'-methoxyethoxy termini) which was essentially inactive at 20 microM. The rank efficiency order of the remaining antisense compounds was 4 = 3 >> 9 >> 10 = 8 = 5 = 6 > 11. The efficient antisense effects induced by the chimeric methylphosphonate-phosphodiester compounds were found to be highly specific. Increased phosphorothioate content in the oligonucleotide backbone correlated with reduced antisense activity (efficacy: 2'- methoxyethoxy series 9 >> 8 >> 7, 2'-methoxytriethoxy series 10 > 11). No consistent evidence was obtained for increased activity correlating with increased oligonucleotide-mRNA heteroduplex thermal stability. In conclusion, the chimeric methylphosphonate-phosphodiester oligodeoxynucleotides present the most favourable characteristics of the compounds tested, for efficient and specific antisense suppression of gene expression following SLO-mediated delivery.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
A. K. Chen, M. A. Behlke, and A. Tsourkas
Efficient cytosolic delivery of molecular beacon conjugates and flow cytometric analysis of target RNA
Nucleic Acids Res., July 1, 2008; 36(12): e69 - e69.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
D. M. Tidd, C. M. Broughton, and R. E. Clark
CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis
Nucleic Acids Res., May 1, 2003; 31(9): 2297 - 2304.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. Dias and C. A. Stein
Antisense Oligonucleotides: Basic Concepts and Mechanisms
Mol. Cancer Ther., March 1, 2002; 1(5): 347 - 355.
[Full Text] [PDF]


Home page
Nucleic Acids ResHome page
T.-C. Mou and D. M. Gray
The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2'-O-methyl modifications
Nucleic Acids Res., February 1, 2002; 30(3): 749 - 758.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
B. H. Lloyd, R. V. Giles, D. G. Spiller, J. Grzybowski, D. M. Tidd, and D. R. Sibson
Determination of optimal sites of antisense oligonucleotide cleavage within TNF{alpha} mRNA
Nucleic Acids Res., September 1, 2001; 29(17): 3664 - 3673.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. J. Stephens and R. Pepperkok
The many ways to cross the plasma membrane
PNAS, March 22, 2001; (2001) 81065198.
[Full Text]


Home page
BloodHome page
D. A. Moulding, R. V. Giles, D. G. Spiller, M. R. H. White, D. M. Tidd, and S. W. Edwards
Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells
Blood, September 1, 2000; 96(5): 1756 - 1763.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
D. M. Tidd, D. G. Spiller, C. M. Broughton, L. C. Norbury, R. E. Clark, and R. V. Giles
Oligodeoxynucleotide 5mers containing a 5'-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells
Nucleic Acids Res., June 1, 2000; 28(11): 2242 - 2250.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
V. Arora, D. C. Knapp, B. L. Smith, M. L. Statdfield, D. A. Stein, M. T. Reddy, D. D. Weller, and P. L. Iversen
c-Myc Antisense Limits Rat Liver Regeneration and Indicates Role for c-Myc in Regulating Cytochrome P-450 3A Activity
J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 921 - 928.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. J. Stephens and R. Pepperkok
The many ways to cross the plasma membrane
PNAS, April 10, 2001; 98(8): 4295 - 4298.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.